

## Medicines for COVID-19

| Section                                                  | Indications |
|----------------------------------------------------------|-------------|
| Medicines for COVID-19<br>Refer to WHO living guidelines | COVID-19    |

## Abacavir

| Section                                                                                                              | Indications                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>Oral > Solid: 300 mg tablet (as sulfate) | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Abacavir + lamivudine

| Section                                                                                                              | Indications                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored) | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Abacavir + lamivudine + lopinavir + ritonavir

| Section                                                                                                                    | Indications                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Aciclovir

| Section                                                                                                                                                                             | Indications                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Antiherpes medicines<br>Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)<br>Oral > Liquid: 200 mg per 5 mL<br>Oral > Solid: 200 mg tablet | Zoster<br>Varicella<br>Herpes simplex infections |

## Albendazole

| Section                                                                                                                                  | Indications                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Intestinal anthelmintics</b><br>Oral > Solid > tablet: 400 mg (chewable, scored)<br>Oral > Solid > tablet: 400 mg (chewable, scored)) | <div>Echinococcosis</div> <div>Ascariasis</div> <div>Enterobiasis</div> <div>Trichuriasis</div> <div>Hookworm diseases</div> <div>Cysticercosis</div> |
| <b>Cysticidal medicines</b><br>Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)                                       | <div>Other specified echinococcosis</div> <div>Cysticercosis of central nervous system</div>                                                          |
| <b>Antifilarials</b><br>Oral > Solid > tablet: 400 mg (chewable, scored)                                                                 | <div>Filariasis</div>                                                                                                                                 |

## Amikacin

| Section                                                                                                                                                                                                                                                     | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Antituberculosis medicines</b><br>Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)                                                                                                                                 | <div>Multi-drug resistant Mycobacterium tuberculosis</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Access group antibiotics</b><br>Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)<br>Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate) | <div>Premier choix</div> <div>Neutropenia (high-risk)</div> <div>co-prescrire avec cefotaxime</div> <div>Acute pyelonephritis (severe)</div> <div>co-prescrire avec cefotaxime</div> <div>Inflammatory and other diseases of prostate (severe)</div> <div>co-prescrire avec ceftriaxone</div> <div>Acute pyelonephritis (severe)</div> <div>co-prescrire avec ceftriaxone</div> <div>Inflammatory and other diseases of prostate (severe)</div> <div>Second choix</div> <div>co-prescrire avec cloxacillin</div> <div>Sepsis without septic shock</div> |

## Amodiaquine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Amodiaquine + sulfadoxine + pyrimethamine

### Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1]  
dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg  
+ 25 mg [1] dispersible tablets in co-package

### Indications

Malaria

## Amoxicillin

### Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250  
mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous)  
capsule or tablet

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250  
mg per 5 mL (as trihydrate) powder for oral liquid

Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)

Parenteral > General injections > unspecified: 250 mg in vial (as sodium)  
powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g  
in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg  
(scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

### Indications

#### Premier choix

Bacterial pneumonia (Community-acquired  
pneumonia - mild to moderate)

Acute sinusitis

Acute otitis media

Periapical abscess without sinus

Acute malnutrition in infants, children or  
adolescents (complicated) [children]

Chronic obstructive pulmonary disease with  
acute exacerbation

Acute malnutrition in infants, children or  
adolescents (uncomplicated) [children]

Acute pharyngitis

co-prescrire avec [gentamicin](#)

Bacterial pneumonia (Community-acquired  
pneumonia - severe) [children]

co-prescrire avec [gentamicin](#)

Sepsis without septic shock

#### Second choix

Bacterial meningitis

#### Autres indications

Bacterial infection of unspecified site

Infectious cystitis

## Amoxicillin + clavulanic acid

### Section

#### Access group antibiotics

Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid

Oral > Solid: 500 mg + 125 mg tablet

Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid

Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)

Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid

#### Antituberculosis medicines

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)

### Indications

#### Premier choix

Peritonitis (mild-moderate)

Bacterial cellulitis, erysipelas or lymphangitis

Neutropenia (low-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Peritoneal abscess (mild-moderate)

Infectious cystitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Acute sinusitis

Chronic obstructive pulmonary disease with acute exacerbation

#### Second choix

Osteomyelitis or osteitis

Other specified prophylactic measures

Bacterial infection of joint

Acute otitis media

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

co-prescrire avec clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Autres indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

## Amphotericin B

### Section

#### Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

#### Antileishmaniasis medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

### Indications

Blastomycosis

Cryptococcosis

Candidosis

Coccidioidomycosis

Histoplasmosis

Sporotrichosis

Aspergillosis

Visceral leishmaniasis

## Ampicillin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension

Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

### Indications

#### Premier choix

co-prescrire avec [gentamicin](#)

Peritoneal abscess (severe)

co-prescrire avec [gentamicin](#)

Sepsis without septic shock

co-prescrire avec [gentamicin](#)

Peritoneal abscess (mild-moderate)

co-prescrire avec [gentamicin](#)

Peritonitis (severe)

co-prescrire avec [gentamicin](#)

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescrire avec [gentamicin](#)

Peritonitis (mild-moderate)

co-prescrire avec [gentamicin](#)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

#### Second choix

Bacterial meningitis

#### Autres indications

Bacterial infection of unspecified site

## Anidulafungin

### Section

Antifungal medicines

### Indications

Therapeutic equivalent to micafungin pour

Systemic or invasive candidosis

## Ansuvimab

### Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 400 mg powder for injection

### Indications

Ebola virus disease

## Artemether

### Section

Antimalarial medicines > For curative treatment

Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Artemether + lumefantrine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Artesunate

### Section

Antimalarial medicines > For curative treatment

Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution

Oral > Solid: 50 mg tablet

Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Artesunate + amodiaquine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Artesunate + mefloquine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Artesunate + pyronaridine tetraphosphate

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Atazanavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atazanavir + ritonavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atoltivimab + maftivimab + odesivimab

### Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

### Indications

Ebola virus disease

## Azithromycin

### Section

#### Watch group antibiotics

Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Oral > Liquid: 200 mg per 5 mL oral liquid

Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule

Oral > Solid > dosage form: 500 mg (anhydrous); 250 mg (anhydrous)

### Indications

#### Premier choix

Yaws

Trachoma

Typhoid fever

Paratyphoid fever

Chlamydia trachomatis

Cholera

Cholera [children]

co-prescrire avec ceftriaxone

Gonococcal infection

#### Second choix

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescrire avec cefixime

Gonococcal infection

## Aztreonam

### Section

#### Reserve group antibiotics

Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

### Indications

Other specified bacterial diseases

## Bedaquiline

### Section

#### Antituberculosis medicines

Oral > Solid: 100 mg tablet; 20 mg tablet

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Benzathine benzylpenicillin

### Section

#### Access group antibiotics

Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)

### Indications

#### Premier choix

Syphilis

Congenital syphilis [children]

#### Autres indications

Bacterial infection of unspecified site



## Benznidazole

### Section

American trypanosomiasis

Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

### Indications

Chagas disease

## Benzylpenicillin

### Section

Access group antibiotics

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

### Indications

#### Premier choix

Congenital syphilis [children]

Syphilis

co-prescrire avec [gentamicin](#)

Sepsis without septic shock

co-prescrire avec [gentamicin](#)

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescrire avec [gentamicin](#)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

#### Second choix

Bacterial meningitis

#### Autres indications

Bacterial infection of unspecified site

## Capreomycin

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Caspofungin

### Section

Antifungal medicines

### Indications

Therapeutic equivalent to micafungin pour

Systemic or invasive candidosis

## Cefalexin

### Section

#### Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (as monohydrate)

Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)

Oral > Solid > dispersible tablet: 125 mg; 250 mg

### Indications

#### Premier choix

Bacterial cellulitis, erysipelas or lymphangitis

#### Second choix

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

#### Autres indications

Bacterial infection of unspecified site

## Cefazolin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

### Indications

#### Premier choix

Other specified prophylactic measures

co-prescrire avec metronidazole

Other specified prophylactic measures

#### Second choix

Osteomyelitis or osteitis

Bacterial infection of joint

#### Autres indications

Surgical site infection

## Cefepime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

### Indications

Other specified bacterial diseases

## Cefiderocol

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

### Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Cefixime

### Section

#### Watch group antibiotics

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

### Indications

#### Second choix

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescrire avec [azithromycin](#)

Gonococcal infection

## Cefotaxime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

### Indications

#### Premier choix

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec amikacin

Inflammatory and other diseases of prostate (severe)

co-prescrire avec amikacin

Acute pyelonephritis (severe)

co-prescrire avec clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescrire avec metronidazole

Peritoneal abscess (severe)

co-prescrire avec metronidazole

Peritoneal abscess (mild-moderate)

co-prescrire avec metronidazole

Peritonitis (severe)

co-prescrire avec metronidazole

Peritonitis (mild-moderate)

#### Second choix

Osteomyelitis or osteitis

Bacterial infection of joint

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

#### Autres indications

Bacterial infection of unspecified site

## Ceftaroline

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

### Indications

Other specified bacterial diseases

## Ceftazidime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

### Indications

#### Premier choix

co-prescrire avec [vancomycin](#)

[Endophthalmitis](#)

#### Autres indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

## Ceftazidime + avibactam

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

### Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

[Carbapenem resistant Enterobacterales](#)

## Ceftolozane + tazobactam

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

### Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

## Ceftriaxone

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

### Indications

#### Premier choix

[Other specified pneumonia \(Hospital-acquired pneumonia\)](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

[Typhoid fever](#)

[Paratyphoid fever](#)

[Bacterial meningitis](#)

co-prescrire avec [amikacin](#)

[Inflammatory and other diseases of prostate \(severe\)](#)

co-prescrire avec [amikacin](#)

[Acute pyelonephritis \(severe\)](#)

co-prescrire avec [azithromycin](#)

[Gonococcal infection](#)

co-prescrire avec [clarithromycin](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

co-prescrire avec [metronidazole](#)

Peritoneal abscess (mild-moderate)

co-prescrire avec [metronidazole](#)

Peritonitis (severe)

co-prescrire avec [metronidazole](#)

Peritoneal abscess (severe)

co-prescrire avec [metronidazole](#)

Necrotising fasciitis

co-prescrire avec [metronidazole](#)

Peritonitis (mild-moderate)

co-prescrire avec [vancomycin](#)

Endophthalmitis

#### Second choix

Bacterial infection of joint

Osteomyelitis or osteitis

Acute pyelonephritis (mild to moderate)

Inflammatory and other diseases of prostate (mild to moderate)

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

#### Autres indications

Bacterial infection of unspecified site

## Cefuroxime

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

### Indications

#### Second choix

Other specified prophylactic measures

## Chloramphenicol

### Section

#### [Access group antibiotics](#)

Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)

Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection

Oral > Liquid: 150 mg per 5 mL (as palmitate)

Oral > Solid: 250 mg capsule

### Indications

#### Second choix

Bacterial meningitis

#### Autres indications

Bacterial infection of unspecified site

## Chloroquine

### Section

#### [Antimalarial medicines > For chemoprevention](#)

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate)

#### [Antimalarial medicines > For curative treatment](#)

Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Malaria due to Plasmodium ovale

Malaria due to Plasmodium malariae

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Ciprofloxacin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

### Indications

#### Premier choix

Typhoid fever

Neutropenia (low-risk)

Paratyphoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Acute pyelonephritis (mild to moderate)

Inflammatory and other diseases of prostate (mild to moderate)

#### Second choix

Cholera

Cholera [children]

co-prescrire avec metronidazole

Peritoneal abscess (mild-moderate)

co-prescrire avec metronidazole

Peritonitis (mild-moderate)

#### Autres indications

Bacterial infection of unspecified site

## Clarithromycin

### Section

#### Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid: 500 mg

Oral > Solid > dosage form: 500 mg

### Indications

#### Premier choix

co-prescrire avec cefotaxime

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescrire avec ceftriaxone

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Second choix

Acute pharyngitis

co-prescrire avec amoxicillin + clavulanic acid

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Autres indications

Helicobacter pylori associated gastric ulcer



## Clindamycin

### Section

#### Access group antibiotics

Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride) capsule

Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)

Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

### Indications

#### Premier choix

co-prescrire avec [piperacillin + tazobactam](#)

Necrotising fasciitis

#### Second choix

Osteomyelitis or osteitis

Bacterial infection of joint

#### Autres indications

Bacterial infection of unspecified site

## Clofazimine

### Section

#### Antituberculosis medicines

Oral > Solid: 100 mg; 50 mg

#### Antileprosy medicines

Oral > Solid: 100 mg; 50 mg

### Indications

Multi-drug resistant Mycobacterium tuberculosis

Leprosy

## Clotrimazole

### Section

#### Antifungal medicines

Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

### Indications

Vulvovaginal candidosis

## Cloxacillin

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Indications                                                                                                                                                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Access group antibiotics</b><br>Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid<br>Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule<br>Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection<br>Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid<br>Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection<br>Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt) | <b>Premier choix</b><br>Bacterial infection of joint<br>Osteomyelitis or osteitis<br>Bacterial cellulitis, erysipelas or lymphangitis<br><b>Second choix</b><br>co-prescrire avec amikacin<br>Sepsis without septic shock<br><b>Autres indications</b><br>Bacterial infection of unspecified site |

## Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

| Section                                                                                                                                                                        | Indications                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| <b>Fixed-dose combinations of antiretrovirals</b><br>Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil) | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

| Section                                                                                             | Indications                                                                                                         |
|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| <b>Fixed-dose combinations of antiretrovirals</b><br>Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Colistin (injection)

| Section                                                                                                                                                                                                                                                                           | Indications                                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Reserve group antibiotics</b><br>Parenteral > General injections > unspecified: 1 million IU in vial (as colistimethate sodium)<br>Parenteral > General injections > unspecified: 1 million IU in vial (as colistimethate sodium) (equivalent to 34 mg colistin base activity) | Other specified bacterial diseases<br>Carbapenem resistant Acinetobacter baumannii<br>Carbapenem-resistant Pseudomonas aeruginosa<br>Carbapenem resistant Enterobacterales |

## Cycloserine

### Section

Antituberculosis medicines

Oral > Solid: 250 mg; 125 mg

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Daclatasvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)

### Indications

Chronic hepatitis C

## Daclatasvir + sofosbuvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 60 mg + 400 mg

### Indications

Chronic hepatitis C

## Dapsone

### Section

Antileprosy medicines

Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

### Indications

Leprosy

## Daptomycin

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

### Indications

Other specified bacterial diseases

## Darunavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dasabuvir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
Oral > Solid: 250 mg tablet

### Indications

Chronic hepatitis C

## Delafloxacin

### Section

Watch group antibiotics  
Parenteral > General injections > IV: 300 mg lyophilized powder for injection  
Oral > Solid: 450 mg

### Indications

Methicillin resistant *Staphylococcus aureus*

## Delamanid

### Section

Antituberculosis medicines  
Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Didanosine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution  
Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Diethylcarbamazine

### Section

Antifilarials  
Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

### Indications

Lymphatic filariasis

## Dihydroartemisinin + piperaquine phosphate

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Diloxanide

### Section

Antiamoebic and anti giardiasis medicines

Oral > Solid: 500 mg (furoate)

### Indications

Amoebiasis

## Dolutegravir

### Section

Antiretrovirals > Integrase inhibitors

Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dolutegravir + lamivudine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Doxycycline

### Section

#### Access group antibiotics

Oral > Solid: 100 mg (as hyclate)

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)

Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)

Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

#### Antimalarial medicines > For curative treatment

Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

#### Antimalarial medicines > For chemoprevention

Oral > Solid: 100 mg (hydrochloride or hyclate)

### Indications

#### Premier choix

Cholera

Chlamydia trachomatis

#### Second choix

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Cholera [children]

Chronic obstructive pulmonary disease with acute exacerbation

#### Autres indications

Bacterial infection of unspecified site

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

## Efavirenz

### Section

#### Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Solid: 600 mg tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + emtricitabine + tenofovir

### Section

#### Fixed-dose combinations of antiretrovirals

Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + lamivudine + tenofovir

### Section

#### Fixed-dose combinations of antiretrovirals

Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine + tenofovir pour

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Eflornithine

### Section

#### Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

### Indications

African trypanosomiasis

## Elbasvir + grazoprevir

### Section

#### Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 100 mg

### Indications

Chronic hepatitis C

## Emtricitabine

### Section

#### Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 10 mg per mL

Oral > Solid: 200 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir alafenamide

### Section

#### Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 25 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

### Section

#### Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + tenofovir

### Section

#### Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

## Emtricitabine + tenofovir alafenamide

### Section

#### Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Entecavir

### Section

#### Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 0.05 mg per mL

Oral > Solid: 0.5 mg; 1 mg

### Indications

Chronic hepatitis B

## Eravacycline

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 50 mg lyophilized powder for injection

### Indications

Carbapenem resistant Enterobacterales

## Erythromycin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

### Indications

#### Second choix

Therapeutic equivalent to [clarithromycin](#) pour

Acute pharyngitis

#### Autres indications

Bacterial infection of unspecified site



## Ethambutol

### Section

#### Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL

Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)

### Indications

Other specified tuberculosis

Tuberculosis

## Ethambutol + isoniazid

### Section

#### Antituberculosis medicines

Oral > Solid: 400 mg + 150 mg tablet

### Indications

Tuberculosis

## Ethambutol + isoniazid + pyrazinamide + rifampicin

### Section

#### Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

### Indications

Tuberculosis

## Ethambutol + isoniazid + rifampicin

### Section

#### Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 150 mg tablet

### Indications

Tuberculosis

## Ethionamide

### Section

#### Antituberculosis medicines

Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)

### Indications

Multi-drug resistant Mycobacterium tuberculosis

Tuberculous meningitis

## Fexinidazole

### Section

#### Medicines for the treatment of 1st stage African trypanosomiasis

Oral > Solid: 600 mg

#### Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid: 600 mg

### Indications

African trypanosomiasis

African trypanosomiasis

## Fifth generation cephalosporins

| Section                        | Indications                        |
|--------------------------------|------------------------------------|
| Reserve group antibiotics<br>. | Other specified bacterial diseases |

## Flomoxef

| Section                                                                                                                               | Indications                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| Watch group antibiotics<br>Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection | Other specified other antibiotic resistant Enterobacterales |

## Fluconazole

| Section                                                                                                                                                                                    | Indications                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| Antifungal medicines<br>Parenteral > General injections > IV: 2 mg per mL in vial<br>Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid<br>Oral > Solid > capsule: 50 mg | Cryptococcosis<br>Candidosis |

## Flucytosine

| Section                                                                                                                 | Indications    |
|-------------------------------------------------------------------------------------------------------------------------|----------------|
| Antifungal medicines<br>Parenteral > General injections > IV: 2.5 g per 250 mL infusion<br>Oral > Solid: 250 mg capsule | Cryptococcosis |

## Fosfomycin (injection)

| Section                                                                                                                                                       | Indications                                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Reserve group antibiotics<br>Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection | Other specified bacterial diseases<br>Carbapenem resistant Acinetobacter baumannii<br>Carbapenem-resistant Pseudomonas aeruginosa<br>Carbapenem resistant Enterobacterales |

## Fourth generation cephalosporins

| Section                      | Indications                        |
|------------------------------|------------------------------------|
| Watch group antibiotics<br>. | Other specified bacterial diseases |

## Gatifloxacin

### Section

Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Gentamicin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

### Indications

#### Premier choix

Neonatal meningitis

co-prescrire avec amoxicillin

Sepsis without septic shock

co-prescrire avec amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec ampicillin

Peritoneal abscess (mild-moderate)

co-prescrire avec ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec ampicillin

Peritoneal abscess (severe)

co-prescrire avec ampicillin

Peritonitis (severe)

co-prescrire avec ampicillin

Sepsis without septic shock

co-prescrire avec ampicillin

Peritonitis (mild-moderate)

co-prescrire avec ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescrire avec benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescrire avec benzylpenicillin

Sepsis without septic shock

#### Second choix

Other specified prophylactic measures

Gonococcal infection

#### Autres indications

Bacterial infection of unspecified site

## Glecaprevir + pibrentasvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules

### Indications

Chronic hepatitis C

## Griseofulvin

### Section

Antifungal medicines

Oral > Liquid: 125 mg per 5 mL

Oral > Solid: 125 mg; 250 mg

### Indications

Dermatophytosis

## Hydroxychloroquine

### Section

Antimalarial medicines > For chemoprevention

### Indications

Therapeutic equivalent to chloroquine pour

Malaria due to *Plasmodium falciparum*

## Imipenem + cilastatin

### Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

### Indications

#### Second choix

Therapeutic equivalent to meropenem pour

Neutropenia (high-risk)

Therapeutic equivalent to meropenem pour

Peritoneal abscess (severe)

Therapeutic equivalent to meropenem pour

Peritonitis (severe)

#### Autres indications

*Pseudomonas aeruginosa* resistant to other antibiotic

Antibiotic resistant *Acinetobacter baumannii*

Antituberculosis medicines

Therapeutic equivalent to meropenem pour

Multi-drug resistant *Mycobacterium tuberculosis*

## Imipenem + cilastatin + relebactam

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection

### Indications

Other specified other antibiotic resistant Enterobacterales

Carbapenem resistant Enterobacterales

Carbapenem-resistant Pseudomonas aeruginosa

## Indinavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 400 mg (as sulfate)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Isoniazid

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 100 mg per mL

Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet

### Indications

Other specified tuberculosis

Tuberculosis

## Isoniazid + pyrazinamide + rifampicin

### Section

Antituberculosis medicines

Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)

### Indications

Tuberculosis

## Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

### Section

Medicines for prevention of HIV-related opportunistic infections

Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

### Indications

Other specified prophylactic measures

## Isoniazid + rifampicin

### Section

Antituberculosis medicines

Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet

### Indications

Tuberculosis

## Isoniazid + rifapentine

### Section

Antituberculosis medicines

Oral > Solid: 300 mg + 300 mg tablet (scored)

### Indications

Latent tuberculosis

## Itraconazole

### Section

Antifungal medicines

Oral > Liquid: 10 mg per mL

Oral > Solid: 100 mg

### Indications

Chronic pulmonary aspergillosis

Chromoblastomycosis

Histoplasmosis

Talaromycosis

Sporotrichosis

Paracoccidioidomycosis

## Ivermectin

### Section

Intestinal anthelmintics

Oral > Solid > tablet: 3 mg

### Indications

Strongyloidiasis

Ascariasis

Trichuriasis

Hookworm diseases

Ancylostomiasis

Antifilarials

Oral > Solid > tablet: 3 mg

Onchocerciasis

Lymphatic filariasis

Medicines for ectoparasitic infections

Oral > Solid > tablet: 3 mg

Scabies

## Kanamycin (injection)

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Lamivudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 150 mg tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lamivudine + nevirapine + zidovudine

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg

Tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lamivudine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals

Therapeutic equivalent to emtricitabine + tenofovir pour

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to emtricitabine + tenofovir pour

Contact with or exposure to human immunodeficiency virus

## Lamivudine + zidovudine

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ledipasvir + sofosbuvir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 90 mg + 400 mg tablet

### Indications

Chronic hepatitis C

## Levamisole

### Section

Intestinal anthelmintics

Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

### Indications

Ascariasis



## Levofloxacin

### Section

#### Antituberculosis medicines

Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Linezolid

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 400 mg tablet; 600 mg tablet

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

#### Antituberculosis medicines

Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)

### Indications

Other specified bacterial diseases

Methicillin resistant *Staphylococcus aureus*

Vancomycin resistant *Staphylococcus aureus*

Vancomycin resistant *Enterococcus*

Multi-drug resistant *Mycobacterium tuberculosis*

## Lopinavir + ritonavir

### Section

#### Antiretrovirals > Protease inhibitors

Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Mebendazole

### Section

#### Intestinal anthelmintics

Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

### Indications

Ascariasis

Enterobiasis

Trichuriasis

Hookworm diseases

#### Cysticidal medicines

Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)

Other specified echinococcosis

## Mefloquine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 250 mg tablet (hydrochloride)

Antimalarial medicines > For chemoprevention

Oral > Solid: 250 mg tablet (hydrochloride)

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Malaria due to *Plasmodium falciparum*

## Meglumine antimoniate

### Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

### Indications

Visceral leishmaniasis

Cutaneous leishmaniasis

Mucocutaneous leishmaniasis

## Melarsoprol

### Section

Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

### Indications

African trypanosomiasis

## Meropenem

### Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Antituberculosis medicines

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

### Indications

#### Second choix

Neutropenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

Neonatal meningitis

Multi-drug resistant *Mycobacterium tuberculosis*

## Meropenem + vaborbactam

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

### Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

## Metronidazole

### Section

#### Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Oral > Solid: 200 to 500 mg tablet

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial  
Injection

Local > Rectal > Suppository: 500 mg suppository; 1 g suppository

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Local > Rectal > Suppository: 1 g suppository; 500 mg suppository

#### Antiamoebic and anti giardiasis medicines

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Parenteral > General injections > unspecified: 500 mg in 100 mL vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

### Indications

#### Premier choix

Trichomoniasis

Intestinal infections due to Clostridioides difficile

co-prescrire avec cefazolin

Other specified prophylactic measures

co-prescrire avec cefotaxime

Peritoneal abscess (mild-moderate)

co-prescrire avec cefotaxime

Peritoneal abscess (severe)

co-prescrire avec cefotaxime

Peritonitis (severe)

co-prescrire avec cefotaxime

Peritonitis (mild-moderate)

co-prescrire avec ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescrire avec ceftriaxone

Peritoneal abscess (severe)

co-prescrire avec ceftriaxone

Peritonitis (mild-moderate)

co-prescrire avec ceftriaxone

Necrotising fasciitis

co-prescrire avec ceftriaxone

Peritonitis (severe)

#### Second choix

co-prescrire avec ciprofloxacin

Peritoneal abscess (mild-moderate)

co-prescrire avec ciprofloxacin

Peritonitis (mild-moderate)

#### Autres indications

Bacterial infection of unspecified site

Amoebiasis

## Micafungin

### Section

#### Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

### Indications

Systemic or invasive candidosis

## Miltefosine

### Section

#### Antileishmaniasis medicines

Oral > Solid: 10 mg; 50 mg

### Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

## Moxifloxacin

### Section

#### Antituberculosis medicines

Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)

Oral > Solid: 400 mg tablet

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Tuberculosis

## Nalidixic acid

### Section

#### Anti-infective medicines

Oral > Solid: 250 mg; 500 mg

### Indications

*Shigella* resistant to unspecified antibiotic

## Nelfinavir

### Section

#### Antiretrovirals > Protease inhibitors

Oral > Solid: 250 mg (as mesilate)

Oral > Other: 50 mg per g oral powder

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Nevirapine

### Section

#### Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL oral solution

Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Niclosamide

### Section

#### Intestinal anthelmintics

Oral > Solid: 500 mg tablet (chewable)

### Indications

Hymenolepiasis

Diphyllobothriasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

## Nifurtimox

### Section

#### Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)

#### American trypanosomiasis

Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

### Indications

African trypanosomiasis

Chagas disease

## Nitrofurantoin

### Section

#### Access group antibiotics

Oral > Liquid: 25 mg per 5 mL oral liquid

Oral > Solid > dosage form: 100 mg; 50 mg

### Indications

#### Premier choix

Infectious cystitis

## Nystatin

### Section

#### Antifungal medicines

Oral > Liquid: 100000 IU per mL

Local > Topical > Other: 100000 IU pessary

Oral > Solid > dosage form: 500000 IU

Oral > Solid > lozenge: 100000 IU

### Indications

Candidosis

## Ofloxacin

### Section

#### Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Omadacycline

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 100 mg lyophilized powder for injection

Oral > Solid: 300 mg

### Indications

Methicillin resistant *Staphylococcus aureus*

## Ombitasvir + paritaprevir + ritonavir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

### Indications

Chronic hepatitis C

## Oseltamivir

### Section

Other antivirals

Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

### Indications

Influenza due to identified seasonal influenza virus

## Oxamniquine

### Section

Antischistosomal and other antitremitode medicines

Oral > Liquid: 250 mg per 5 mL

Oral > Solid: 250 mg capsule

### Indications

Schistosomiasis due to *Schistosoma mansoni*

## Oxazolidinones

### Section

Reserve group antibiotics

.

### Indications

Other specified bacterial diseases

## P-aminosalicylate sodium

### Section

Antituberculosis medicines

Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## P-aminosalicylic acid

### Section

#### Antituberculosis medicines

Oral > Solid: 4 g granules in sachet

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Paromomycin

### Section

#### Antileishmaniasis medicines

Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

#### Antiamoebic and anti giardiasis medicines

Oral > Liquid: 125 mg per 5 mL as sulfate

Oral > Solid: 250 mg as sulfate

### Indications

Visceral leishmaniasis

Amoebiasis

## Pegylated interferon alfa (2a)

### Section

#### Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pegylated interferon alfa (2b)

### Section

#### Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pentamidine

### Section

#### Antileishmaniasis medicines

Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)

#### Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 200 mg tablet; 300 mg tablet

#### Medicines for the treatment of 1st stage African trypanosomiasis

Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection

### Indications

Visceral leishmaniasis

Pneumocystosis

African trypanosomiasis



## Phenoxymethylpenicillin

### Section

#### Access group antibiotics

Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 250 mg (as potassium salt) tablet

Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

### Indications

#### Premier choix

Acute pharyngitis

Periapical abscess without sinus

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

#### Autres indications

Bacterial infection of unspecified site

## Piperacillin + tazobactam

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

### Indications

#### Premier choix

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropenia (high-risk)

Peritonitis (severe)

co-prescrire avec clindamycin

Necrotising fasciitis

## Plazomicin

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL (Injection)

### Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Polymyxin B (injection)

### Section

#### Reserve group antibiotics

Parenteral > General injections > unspecified: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

### Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Polymyxins

### Section

Reserve group antibiotics

### Indications

Other specified bacterial diseases

## Potassium iodide

### Section

Antifungal medicines

Local > Topical > Solution: Saturated solution

### Indications

Sporotrichosis

## Praziquantel

### Section

Antischistosomes and other antitremitode medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

### Indications

Paragonimiasis

Clonorchiasis

Opisthorchiasis

Schistosomiasis

Intestinal anthelmintics

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Hymenolepiasis

Diphyllobothriasis

Cysticidal medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Cysticercosis of central nervous system

## Pretomanid

### Section

Antituberculosis medicines

Oral > Solid > tablet: 200 mg

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Primaquine

### Section

Antimalarial medicines > For curative treatment

Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)

### Indications

Malaria due to *Plasmodium ovale*

Malaria due to *Plasmodium vivax*

## Procaine benzylpenicillin

### Section

Access group antibiotics

Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

### Indications

Premier choix

Congenital syphilis [children]

Second choix

Syphilis

## Proguanil

### Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 100 mg tablet (hydrochloride)

### Indications

Malaria due to *Plasmodium falciparum*

## Protionamide

### Section

Antituberculosis medicines

### Indications

Therapeutic equivalent to *ethionamide* pour

Multi-drug resistant *Mycobacterium tuberculosis*

## Pyrantel

### Section

Intestinal anthelmintics

Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

### Indications

Ascariasis

Trichuriasis

Enterobiasis

Hookworm diseases

## Pyrazinamide

### Section

Antituberculosis medicines

Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg

### Indications

Tuberculosis

## Pyrimethamine

### Section

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 25 mg

### Indications

Toxoplasmosis

## Quinine

### Section

[Antimalarial medicines](#) > For curative treatment

Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)

Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)

### Indications

Malaria due to *Plasmodium falciparum*

## Raltegravir

### Section

[Antiretrovirals](#) > Integrase inhibitors

Oral > Liquid: 100 mg granules for oral suspension

Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ravidasvir

### Section

[Medicines for hepatitis C](#) > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg

### Indications

Chronic hepatitis C

## Ribavirin

### Section

[Other antivirals](#)

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

[Medicines for hepatitis C](#) > [Other antivirals for hepatitis C](#)

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

### Indications

Viral haemorrhagic fever, not elsewhere classified

Chronic hepatitis C

## Rifabutin

### Section

[Antituberculosis medicines](#)

Oral > Solid: 150 mg

### Indications

Tuberculosis

## Rifampicin

### Section

#### Antituberculosis medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Parenteral > General injections > IV: 600 mg in vial powder for injection

#### Antileprosy medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

### Indications

Tuberculosis

Other specified tuberculosis

Leprosy

## Rifapentine

### Section

#### Antituberculosis medicines

Oral > Solid: 150 mg tablet; 300 mg tablet

### Indications

Tuberculosis

Latent tuberculosis

## Ritonavir

### Section

#### Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Saquinavir

### Section

#### Antiretrovirals > Protease inhibitors

Oral > Solid: 200 mg; 500 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Simeprevir

### Section

#### Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 150 mg

### Indications

Chronic hepatitis C

## Sodium stibogluconate

### Section

Antileishmaniasis medicines

Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

### Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

## Sofosbuvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 400 mg; 200 mg

### Indications

Chronic hepatitis C

## Sofosbuvir + velpatasvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet

### Indications

Chronic hepatitis C

## Spectinomycin

### Section

Access group antibiotics

Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

### Indications

#### Second choix

Gonococcal infection

#### Autres indications

Bacterial infection of unspecified site

## Stavudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 5 mg per 5 mL powder for oral solution

Oral > Solid: 15 mg; 20 mg; 30 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Streptomycin (injection)

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Sulfadiazine

| Section                                                                                                                                 | Indications                             |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Antipneumocystosis and antitoxoplasmosis medicines<br>Oral > Solid: 500 mg                                                              | Toxoplasmosis                           |
| Anti-infective medicines<br>Oral > Solid: 500 mg<br>Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt) | Bacterial infection of unspecified site |

## Sulfadimidine

| Section                                                                                                                                                                | Indications                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Anti-infective medicines<br>Oral > Liquid: 500 mg per 5 mL<br>Oral > Solid: 500 mg<br>Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt) | Bacterial infection of unspecified site |

## Sulfadoxine + pyrimethamine

| Section                                                                                                                      | Indications                                                             |
|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Antimalarial medicines > For curative treatment<br>Oral > Solid: 500 mg + 25 mg tablet                                       | Malaria due to Plasmodium falciparum<br>Malaria due to Plasmodium vivax |
| Antimalarial medicines > For chemoprevention<br>Oral > Solid: 500 mg + 25 mg tablet<br>Oral > Solid: 250 mg + 12.5 mg tablet | Malaria due to Plasmodium falciparum<br>Malaria                         |

## Sulfamethoxazole + trimethoprim

### Section

#### Access group antibiotics

Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule

Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid

Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet

Oral > Solid > dispersible tablet: 100 mg + 20 mg

#### Antipneumocystosis and antitoxoplasmosis medicines

Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule

Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid

Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet

Oral > Solid > dispersible tablet: 100 mg + 20 mg

### Indications

#### Premier choix

Infectious cystitis

#### Second choix

Infectious gastroenteritis or colitis without specification of infectious agent

#### Autres indications

Bacterial infection of unspecified site

Pneumocystosis

## Suramin sodium

### Section

#### Antifilarials

Parenteral > General injections > IV: 1 g in vial

#### Medicines for the treatment of 1st stage African trypanosomiasis

Parenteral > General injections > IV: 1 g in vial

### Indications

Filariasis

African trypanosomiasis

## Tedizolid

### Section

#### Reserve group antibiotics

### Indications

Therapeutic equivalent to linezolid pour

Methicillin resistant Staphylococcus aureus

Therapeutic equivalent to linezolid pour

Vancomycin resistant Staphylococcus aureus

Therapeutic equivalent to linezolid pour

Vancomycin resistant Enterococcus



## Tenofovir alafenamide

### Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 25 mg

### Indications

Chronic hepatitis B

## Tenofovir disoproxil fumarate

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Chronic hepatitis B

## Terizidone

### Section

Antituberculosis medicines

### Indications

Therapeutic equivalent to cycloserine pour

Multi-drug resistant Mycobacterium tuberculosis

## Tetracycline

### Section

Access group antibiotics  
Oral > Solid: 250 mg (hydrochloride)

### Indications

Bacterial infection of unspecified site

## Tigecycline

### Section

Reserve group antibiotics  
Parenteral > General injections > IV: 50 mg in vial powder for injection

### Indications

Other specified bacterial diseases

## Tinidazole

### Section

Antiamoebic and anti giardiasis medicines

### Indications

Therapeutic equivalent to metronidazole pour

Amoebiasis

## Triclabendazole

### Section

Antischistosomes and other antitrematode medicines

Oral > Solid > tablet: 250 mg (scored)

### Indications

Paragonimiasis

Fascioliasis

## Trimethoprim

### Section

Access group antibiotics

Oral > Liquid: 50 mg per mL

Oral > Solid: 100 mg; 200 mg

### Indications

Premier choix

Infectious cystitis

## Valaciclovir

### Section

Antiherpes medicines

### Indications

Therapeutic equivalent to [aciclovir](#) pour

Zoster

Therapeutic equivalent to [aciclovir](#) pour

Varicella

Therapeutic equivalent to [aciclovir](#) pour

Herpes simplex infections

## Valganciclovir

### Section

Other antivirals

Oral > Liquid: 50 mg per mL powder for oral solution

Oral > Solid: 450 mg Tablet

### Indications

Cytomegaloviral retinitis

## Vancomycin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

### Indications

#### Premier choix

Necrotising fasciitis

co-prescrire avec [ceftazidime](#)

Endophthalmitis

co-prescrire avec [ceftriaxone](#)

Endophthalmitis

#### Second choix

Neutropenia (high-risk)

Intestinal infections due to *Clostridioides difficile*

#### Autres indications

Methicillin resistant *Staphylococcus aureus*

## Voriconazole

### Section

#### Antifungal medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection

Oral > Liquid: 40 mg per mL powder for oral liquid

Oral > Solid: 50 mg tablet; 200 mg tablet

### Indications

Chronic pulmonary aspergillosis

Invasive aspergillosis

## Zidovudine

### Section

#### Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 250 mg capsule; 300 mg tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified